Baird Maintains an 'Outperform' on Affymax (AFFY); Even After Significant Model Revamp, It's Still A Buy
Tweet
Share
E-mailGet Alerts AFFY Hot Sheet
Price: $0.00 --0%
Rating Summary:
3 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
3 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Baird maintains an 'Outperform' on Affymax, Inc. (NASDAQ: AFFY) price target of $13.00.
Baird analyst says, "Mindful of the sometimes swift and brutal stock reactions incurred by newly commercial names that underperform expectations - especially in recent years - we've reduced peginesatide estimates, reflecting a US launch that assumes a protracted piloting period, excludes Fresenius and DaVita uptake (~70% of the market), and prices peginesatide at a healthy 20% discount to Epogen. Even with all that, we still think this stock is more fairly valued in the low teens. Remain buyers."
"New FY12-FY15 US end-user estimates are $21M, $128M, $196M and $271M, respectively."
For an analyst ratings summary and ratings history on Affymax, Inc. click here. For more ratings news on Affymax, Inc. click here.
Shares of Affymax, Inc. closed at $6.56 yesterday.
Baird analyst says, "Mindful of the sometimes swift and brutal stock reactions incurred by newly commercial names that underperform expectations - especially in recent years - we've reduced peginesatide estimates, reflecting a US launch that assumes a protracted piloting period, excludes Fresenius and DaVita uptake (~70% of the market), and prices peginesatide at a healthy 20% discount to Epogen. Even with all that, we still think this stock is more fairly valued in the low teens. Remain buyers."
"New FY12-FY15 US end-user estimates are $21M, $128M, $196M and $271M, respectively."
For an analyst ratings summary and ratings history on Affymax, Inc. click here. For more ratings news on Affymax, Inc. click here.
Shares of Affymax, Inc. closed at $6.56 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- KinderCare Learning Companies (KLC) PT Lowered to $4.50 at UBS
- JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
